AI assistant
Sending…
Kura Oncology, Inc. — Director's Dealing 2021
Jan 28, 2021
32433_dirs_2021-01-28_936b3190-fca0-466e-bb29-636016635a6d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kura Oncology, Inc. (KURA)
CIK: 0001422143
Period of Report: 2021-01-26
Reporting Person: GRASSO MARC (CFO, CBO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-26 | Option to purchase common stock | $32.80 | A | 175000 | Acquired | 2031-01-25 | Common Stock (175000) | Direct |
Footnotes
F1: This option vests in 48 equal monthly installments commencing on the grant date.
More from Kura Oncology, Inc.
Proxy Solicitation & Information Statement
2026
May 26
Annual Report
2026
Apr 10
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 25
Director's Dealing
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 29
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27